⏳ Fetching live dividend data...
Home › Calculator › APLS Dividend Calculator 2026
Apellis Pharmaceuticals, Inc. · NASDAQ
Price: $41.03 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in APLS → $10.75M in 10 years · $42.63/month
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open APLS position with:
Real after-tax yield depends on where you live and how you hold APLS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.87% | 2.07% | $487 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 4.14% | 1.34% | $414 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.90% | 1.10% | $390 / yr |
| 🇬🇧 UK ISA | 0% | 4.87% | 2.07% | $487 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4.44% | 1.64% | $444 / yr |
| 🇨🇦 TFSA | 0% | 4.87% | 2.07% | $487 / yr |
| 🇨🇦 CA Taxable | 25% | 3.65% | 0.85% | $365 / yr |
| 🇦🇺 Super (pension) | 15% | 4.14% | 1.34% | $414 / yr |
| 🇦🇺 AU Taxable | 30% | 3.41% | 0.61% | $341 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.59% | 0.79% | $359 / yr |
| 🇫🇷 FR Taxable | 30% | 3.41% | 0.61% | $341 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
APLS pays quarterly — 4 times per year. Next ex-div: TBD.
How APLS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for APLS sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2026-05-14 | 3,544 | — | — | ||
| D-Return | 2026-05-14 | 14,684 | $25.12 | $368.9K | ||
| D-Return | 2026-05-14 | 27,600 | $30.62 | $845.1K | ||
| D-Return | 2026-05-14 | 11,199 | $31.91 | $357.4K | ||
| D-Return | 2026-05-14 | 8,554 | $47.28 | $404.4K | ||
| U-Tender | 2026-05-14 | 161,567 | $4.00 | $646.3K | ||
| D-Return | 2026-05-14 | 7,441 | $51.71 | $384.8K | ||
| D-Return | 2026-05-14 | 27,600 | $57.20 | $1.58M | ||
| D-Return | 2026-05-14 | 5,748 | $59.86 | $344.1K | ||
| A-Award | 2026-05-14 | 16,150 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the APLS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Apellis Pharmaceuticals, Inc. (APLS) is currently trading at $41.03, 54% below its 52-week high. The current dividend yield is 4.87% based on an annual payout of $2.00 per share.
Apellis Pharmaceuticals, Inc. (APLS) is a healthcare stock currently trading at $41.03 with a dividend yield of 4.87%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →